Search Results
Your search for ,iII matches 9383 pages
Showing 6101 - 6150Eribulin vs Dacarbazine in Advanced Liposarcoma Subgroup
The subgroup analysis of outcomes among patients with advanced liposarcoma from a pivotal phase III trial comparing eribulin (Halaven) vs dacarbazine in previously treated liposarcoma or leiomyosarcoma was reported in the Journal of Clinical Oncology by Demetri et al. Overall, the phase III trial...
ESMO 2017: Adding Taselisib to Neoadjuvant Letrozole Improves Outcomes in Early Breast Cancer
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor–positive and HER2-negative, according to results of the LORELEI trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress ...
ESMO 2017: New Data Confirms Superiority of Docetaxel-Based Triplet Therapy in Esophagogastric Cancer
The superiority of docetaxel-based triplet therapy over standard of care in patients with resectable esophagogastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA27_PR)....
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable non–small cell lung cancer (Abstract LBA1).
Eric Pujade-Lauraine, MD, PhD, on Ovarian Cancer: Results From the SOLO2 Trial
Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer by lines of prior chemotherapy (Abstract 932PD).
ESMO 2017: Combination Targeted Adjuvant Therapy Doubles Relapse-Free Survival in Stage III Melanoma
Combination targeted adjuvant therapy with dabrafenib (Tafinlar) and trametinib (Mekinist) doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented on September 11 at the European Society for Medical Oncology ...
ESMO 2017: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma
Adjuvant nivolumab (Opdivo) is superior to standard-of-care ipilimumab (Yervoy) in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented on September 11 at the European Society for Medical...
Adding First-Line Ipilimumab to Paclitaxel/Carboplatin in Advanced Squamous NSCLC
In a phase III trial reported by Govindan et al in the Journal of Clinical Oncology, the addition of first-line ipilimumab (Yervoy) to paclitaxel/carboplatin did not improve overall survival in patients with advanced squamous non–small cell lung cancer (NSCLC). Study Details In the...
Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial
Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma (Abstract LBA8).
ESMO 2017: MIRO Trial: 3-Year Outcomes Favor Laparoscopic Surgery for Esophageal Cancer
Patients requiring surgery for esophageal cancer fare better after undergoing a hybrid minimally invasive esophagostomy compared to an open esophagostomy, according to long-term results of the MIRO trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract ...
ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer
Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in...
ESMO 2017: ALEX and ALUR Trials: Alectinib Shows CNS Benefit in ALK-Positive NSCLC
Data from two separate phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show the particular central nervous system (CNS) activity of alectinib (Alecensa) in patients with advanced non–small cell lung cancer involving a mutation of the...
Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial
Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (Abstract 929O).
Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial
Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.
Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) for biliary tract cancer (LBA29).
Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial
Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (Abstract 1043O).
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable non–small cell lung cancer (Abstract LBA1).
ESMO 2017: Phase III IFCT-0302 Trial Assesses Minimal vs CT Scan–Based Follow-up for Completely Resected NSCLC
The optimal follow-up protocol for patients with completely resected non–small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, did not show a difference in overall survival...
Health-Related Quality of Life With Everolimus vs Placebo in Patients With Neuroendocrine Tumors
As reported in The Lancet Oncology by Pavel et al, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...
First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Colorectal Cancer
A phase III trial has shown no significant difference in overall survival with first-line cetuximab (Erbitux) vs bevacizumab (Avastin) plus chemotherapy in patients with advanced or metastatic KRAS wild-type colorectal cancer. These study findings were reported by Alan Venook, MD, of University of ...
Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma
The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported by Weller et al...
Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Breast Cancer
The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by ...
‘Substantial Improvements’ in the Treatment of Glioblastoma
NEWS ARTICLES about Senator John McCain’s diagnosis of glioblastoma accurately describe glioblastoma as aggressive and having a poor prognosis. But as Walter J. Curran, Jr, MD, pointed out in one of those reports, “substantial improvements in surgical approaches” have enabled more patients to...
Addressing the Challenges of Intimacy After Cancer
The literature has documented the stress and damage that intimacy problems cause among women undergoing cancer treatment and during survivorship. A new book, Sex and Cancer: Intimacy, Romance, and Love After Diagnosis and Treatment, by Saketh R. Guntupalli, MD, and Maryann Karinch tackles the...
Midostaurin in FLT3 Mutation–Positive Acute Myeloid Leukemia and Systemic Mastocytosis
ON APRIL 28, 2017, midostaurin (Rydapt) was approved for treatment of adults with newly diagnosed acute myeloid leukemia (AML) who have FLT3 mutation–positive disease, as detected by a U.S. Food and Drug Administration (FDA)-approved test, in combination with standard cytarabine and daunorubicin...
Emerging Global Leaders in Biosimilar Development: Regulatory Guidance and Cost Impact
BIOLOGICS PLAY A KEY ROLE in cancer treatment and are the principal components of many therapeutic regimens.1 However, they require complex manufacturing processes, resulting in high cost and occasional shortages in supply, limiting the accessibility of cancer treatment for many patients, more so ...
Positioning Lu-177 Dotatate Therapy and 68-Ga Dotatate Scans in Management of Neuroendocrine Tumors
The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,1 have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium Lu-177 dotatate...
Journal of Clinical Oncology Literature Update
Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer...
Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors
With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...
‘Sidedness’ in Colon Cancer: Using the Data in the Clinic
The evidence from clinical trials has established that “side matters” when it comes to colorectal cancer outcomes. How do clinicians use this information in their practices? Christina Wu, MD, of Emory University, shared her thoughts with attendees at the 2017 Debates and Didactics in Hematology and ...
Recent FDA Actions Include New Formulation, Expanded Indications for Oncology-Hematology Drug Products
The U.S. Food and Drug Administration (FDA) recently granted approval to olaparib tablets (Lynparza) as a maintenance therapy for ovarian cancer and to inotuzumab ozogamicin (Besponsa), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....
Multiple Myeloma: Researchers Are Digging Deeper Than Ever
Researchers are tackling multiple myeloma from many angles, and the result could be a flood of novel approaches soon within the oncologist’s reach, according to Kenneth C. Anderson, MD. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Anderson...
Targeted Treatments and Health-Related Quality of Life in Ovarian Cancer
Novel targeted treatment strategies and new trial endpoints in recurrent, platinum-sensitive ovarian cancer were highlighted in a gynecologic cancer session at the Best of ASCO New Orleans. At the meeting, Karen McLean, MD, PhD, of the University of Michigan Medical Center, Ann Arbor, presented...
Overall Survival With Carfilzomib vs Bortezomib in Relapsed or Refractory Multiple Myeloma
As reported by Dimopoulos et al in The Lancet Oncology, a prespecified interim analysis of the phase III ENDEAVOR trial has shown a significant overall survival benefit for carfilzomib (Kyprolis) vs bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma. Carfilzomib was...
Adding Adjuvant Erlotinib to Gemcitabine After R0 Resection of Pancreatic Cancer
The German phase III CONKO-005 trial has shown no significant benefit of adding adjuvant erlotinib (Tarceva) to gemcitabine after R0 resection in patients with pancreatic ductal adenocarcinoma. The findings were reported in the Journal of Clinical Oncology by Sinn et al. Study Details In the...
Pembrolizumab vs Ipilimumab in Advanced Melanoma: Final Overall Survival Analysis of KEYNOTE-006
The final overall survival analysis of the phase III KEYNOTE-006 trial showed maintained superiority of pembrolizumab (Keytruda) vs ipilimumab (Yervoy) in advanced melanoma. The results were reported by Schachter et al in The Lancet. An interim analysis showed improved progression-free and overall...
Tivozanib Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
On August 28, AVEO Oncology announced that the European Commission (EC) has approved tivozanib (Fotivda) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland. Tivozanib is indicated for the first-line treatment of adult patients with...
Phase III ALCYONE Study of Daratumumab in Front-Line Treatment of Multiple Myeloma
On August 24, positive topline results were announced from the phase III ALCYONE study of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) vs VMP alone as front-line treatment for newly diagnosed patients who are not considered candidates for...
Association of Systemic Inflammation and Sarcopenia With Survival in Early-Stage Colorectal Cancer
Results from the C SCANS (Colorectal Cancer: Sarcopenia, Cancer, and Near-Term Survival) study indicate that prediagnosis systemic inflammation and at-diagnosis sarcopenia are associated with an increased mortality risk in patients with nonmetastatic colorectal cancer. The findings were reported in ...
FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma
On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....
FDA Approves Fulvestrant as Monotherapy for Expanded Use in Breast Cancer
On August 28, the U.S. Food and Drug Administration (FDA) approved fulvestrant (Faslodex) at 500 mg as monotherapy for expanded use in women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who have gone through menopause...
Obinutuzumab vs Rituximab Plus CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma
The phase III GOYA trial has shown no progression-free survival advantage with obinutuzumab (Gazyva) vs rituximab (Rituxan) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced diffuse large B-cell lymphoma (DLBCL). The results were...
Reduced-Dose Cabazitaxel After Docetaxel in Metastatic Castration-Resistant Prostate Cancer
In the phase III PROSELICA trial reported by Eisenberger et al in the Journal of Clinical Oncology, a cabazitaxel (Jevtana) dose of 20 mg/m2 (C20) was noninferior for overall survival vs the currently recommended dose of 25 mg/m2 (C25) after docetaxel treatment in metastatic castration-resistant...
African American Men Have Lowest Survival Rates Among Patients With Anal Cancer
Over the past 30 years, squamous cell carcinoma of the anus has been one of the few cancers with a steadily rising incidence in the United States, with the most rapid increase seen in black men. To further investigate this trend, researchers at the University of Texas Southwestern Medical Center...
Prolonged and Intensified Neoadjuvant Therapy for Esophageal Adenocarcinoma
A UK phase III trial (UK MRC OE05) has shown no significant survival benefit of extended and intensified neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine vs standard cisplatin/fluorouracil followed by resection in patients with esophageal adenocarcinoma. The findings were...
Anti–Trop-2 Antibody-Drug Conjugate Produces Durable Responses in Metastatic Triple-Negative Breast Cancer
AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues, the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily...
Adjuvant Temozolomide in 1p/19q Non-Codeleted Anaplastic Glioma
Interim results of the phase III CATNON trial (EORTC study 26053-22054) indicate a survival benefit of adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma. These findings were reported in The Lancet by van den Bent et al. Study Details In the open-label 2 x 2 factorial trial, 745...
Osimertinib for EGFR-Positive NSCLC: The Phase III FLAURA Trial
RECENTLY ANNOUNCED DATA from the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously...
Detection of Early-Stage Cancers With Circulating Tumor DNA
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...
